Table 1.
Overview of recent clinical trials discussed in this review in patients with resectable esophageal cancer.
| Name | Trial Number | Tumor Type | Setting (Line) | Phase | Population | Treatment Arms | Status |
|---|---|---|---|---|---|---|---|
| CROSS | NTR487 | Esophageal + GEJ carcinoma; both adenocarcinoma and squamous cell carcinoma | Neoadjuvant | III | Europe | Cohort 1: chemoradiotherapy + surgery (paclitaxel + carboplatin) Cohort 2: surgery alone |
Completed |
| FLOT4 | NCT01216644 | Gastric + GEJ adenocarcinoma | Perioperative | II/III | Europe | Cohort 1: FLOT (5-FU + leucovorin + oxaliplatin + docetaxel) Cohort 2: ECF (epirubicin, cisplatin, 5-FU) |
Completed |
| Neo-AEGIS | NCT01726452 | Esophageal + GEJ adenocarcinoma | Neoadjuvant/perioperative | III | Europe | Cohort 1: perioperative chemotherapy Cohort 2: neoadjuvant chemoradiotherapy |
Active, not recruiting |
| ESOPEC | NCT02509286 | Esophageal adenocarcinoma | Neoadjuvant/perioperative | III | Europe | Cohort 1: FLOT + surgery Cohort 2: CROSS + surgery |
Active, not recruiting |
| CheckMate 577 | NCT02743494 | Esophageal + GEJ carcinoma; both adenocarcinoma and squamous cell carcinoma | Post-operative adjuvant | III | North and South America, Australia, Europe, Asia | Cohort 1: nivolumab Cohort 2: placebo |
Active, not recruiting |
| KEYNOTE-585 | NCT03221426 | Gastric + GEJ adenocarcinoma | Perioperative | III | North and South America, Europe, Asia | Cohort 1: pembrolizumab + chemotherapy Cohort 2: placebo + chemotherapy |
Active, not recruiting |
| - | NCT04280822 | Esophageal squamous cell carcinoma | Neoadjuvant | III | Asia | Cohort 1: chemotherapy + toripalimab Cohort 2: chemotherapy |
Recruiting |